Business context and reporting period
Alpha Teknova, Inc. (Nasdaq: TKNO) filed this Form 10-K for the fiscal year ended December 31, 2023. The company manufactures custom and catalog reagents used in life-sciences research and in the development and production of therapies, vaccines, and molecular diagnostics. Its products are grouped into Lab Essentials and Clinical Solutions and are manufactured at its Hollister, California facilities.
Lab Essentials generated $28.8 million, or about 79%, of 2023 revenue; Clinical Solutions generated $6.7 million, or about 18%. The company reported more than 2,500 active customers and approximately 96% retention among customers purchasing over $10,000 annually.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $36.7 million | $41.4 million |
| Gross profit / margin | $10.3 million / 28.1% | $17.5 million / 42.2% |
| Operating loss | $35.6 million | $49.7 million |
| Net loss | $36.8 million | $47.5 million |
| Net loss per share | $1.16 | $1.69 |
| Cash used in operating activities | $18.8 million | $27.4 million |
| Cash used in investing activities | $7.7 million | $28.1 million |
| Cash provided by financing activities | $12.8 million | $10.3 million |
Cash and cash equivalents declined to $28.5 million from $42.2 million. Working capital was $36.8 million. At year-end, term-loan principal was $12.1 million; balance-sheet long-term debt, net, was $13.3 million, including accrued exit fees and net of debt costs. Total liabilities were $38.6 million and stockholders’ equity was $90.0 million. Lease liabilities totaled $17.2 million.
Interest expense, net, was $0.8 million, compared with net interest income of $0.2 million in 2022; 2023 also included a $0.8 million loss on debt extinguishment. The company reported a $0.3 million tax benefit. It had $50.2 million of federal and $53.6 million of state net operating loss carryforwards, subject to limitations.
Material changes versus 2022
- Revenue fell 11.4%. Lab Essentials revenue declined 9.4%, primarily with fewer customers, partly offset by higher average revenue per customer. Clinical Solutions revenue declined 20.2%, primarily with lower average revenue per customer, partly offset by more customers.
- Gross margin fell 14.1 percentage points. Management attributed the decline mainly to lower revenue and reduced absorption of fixed manufacturing costs, along with higher overhead costs.
- Net loss narrowed by $10.7 million, but the comparison benefited from the absence of 2022’s $16.6 million goodwill impairment. In 2023, the company recorded a $2.2 million tradename impairment and $2.2 million of long-lived asset impairment; 2022 included $4.2 million of long-lived asset impairment.
- Operating cash use improved by $8.6 million, while capital expenditures declined substantially. Financing included $22.5 million net proceeds from the September 2023 equity offerings, partly offset by a $10.0 million term-loan repayment. The offerings issued approximately 12.4 million shares.
Outlook, commentary, risks and unusual items
- Going concern: Management and the auditor state that conditions raise substantial doubt about the company’s ability to continue as a going concern for the twelve months following issuance of the financial statements. The company cited recurring losses, limited capital resources, and potential difficulty meeting revenue covenants. The statements were prepared on a going-concern basis and include no related adjustments.
- Debt covenants: In March 2024, MidCap waived specified revenue-covenant violations and reduced the minimum revenue covenant to $34 million through December 2024. Later requirements are to be determined by the lender subject to contractual floors. The minimum cash requirement rose from $9 million to $10 million, and the threshold for the next revolving-loan borrowing fell from $45 million to $38 million. Further covenant noncompliance could permit acceleration of debt; obligations are secured by substantially all company assets. A 125,000-share warrant was issued to the lender in connection with the amendment.
- Cost reductions: A February 2023 reduction affected approximately 40 positions and cost $0.7 million. A January 2024 reduction affected approximately 15% of employees; estimated severance costs are $1.2 million and projected annual savings are $6.4 million. The company cautions that savings and effects on service and turnaround times are uncertain.
- Operating environment: Management cited reduced funding for emerging biotech customers and softer life-sciences spending since mid-2022, as well as inflation and higher interest rates. The company lowered its 2024-and-beyond projections, contributing to the 2023 tradename impairment. It provided no clear revenue or earnings guidance in the supplied filing text.
- Other items: A former employee’s California wage-and-hour claim is subject to a $0.3 million accrual; mediation was scheduled for June 2024. The company reported no material legal proceedings otherwise. A stock-option repricing effective March 2024 will create additional compensation expense, not yet quantified. Management concluded internal controls were effective at year-end and that the prior income-tax-accounting material weakness was remediated.
- Principal risks: Continued operating losses and cash burn; covenant compliance and access to financing; falling demand or customer order cancellations; fixed-cost underutilization and manufacturing scale-up; customer and supplier concentration; dependence on key raw materials; quality, regulatory, and delivery risks; and workforce-reduction impacts. The company also relies primarily on trade secrets rather than issued patents to protect its technology.
Important facts for investors to verify
- Whether operating cash burn declines and revenue stabilizes enough to support liquidity and continued operations.
- Actual covenant thresholds and compliance under the amended credit agreement, available revolver capacity, minimum-cash requirements, and any lender waivers.
- Whether cost reductions deliver the stated savings without impairing manufacturing capacity, customer service, or delivery times.
- Revenue and gross-margin trends by product category, especially Clinical Solutions, and the causes of customer and order-volume changes.
- Potential dilution from the September 2023 equity issuance, future ATM sales, equity awards, and the lender warrant.
- Resolution of the labor claim, future impairment charges, and the expense impact of the 2024 option repricing.